FTC Operation False Cure snares firms
This article was originally published in The Tan Sheet
Executive Summary
The Federal Trade Commission resolves allegations against two businesses that allegedly made unsupported claims their herbal products treated, cured and prevented cancer. An FTC administrative law judge found Mary Spohn, doing business as Surprise, Ariz.-based Herbs for Cancer, guilty of falsely claiming her teas fight at least 16 types of cancer. A separate proposed settlement prohibits El Prado, N.M.-based Native Essence Herb Co. from making misleading and unsupported claims that its "herbal concoctions" treat cancer. The firms must announce the FTC findings to consumers who have bought their products since January 2005
You may also be interested in...
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.